Equitec Proprietary Markets, LLC Pharma Cyte Biotech, Inc. Transaction History
Equitec Proprietary Markets, LLC
- $159 Million
- Q1 2024
A detailed history of Equitec Proprietary Markets, LLC transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Equitec Proprietary Markets, LLC holds 82,727 shares of PMCB stock, worth $172,899. This represents 0.12% of its overall portfolio holdings.
Number of Shares
82,727
Previous 82,727
-0.0%
Holding current value
$172,899
Previous $196,000
-0.0%
% of portfolio
0.12%
Previous 0.11%
Shares
6 transactions
Others Institutions Holding PMCB
# of Institutions
32Shares Held
1.07MCall Options Held
5.4KPut Options Held
400-
K2 Principal Fund, L.P. Toronto, A6328KShares$684,4810.27% of portfolio
-
Geode Capital Management, LLC Boston, MA200KShares$418,5870.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA175KShares$364,9180.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$192,4617.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny43.8KShares$91,5420.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $43.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...